LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will present and host meetings at two upcoming investor conferences.
William Blair’s 46th Annual Growth Stock Conference
Date and time: June 2, 2026; 1:20pm CDT / 7:20pm BST
Location: Chicago, IL
Presenter: Chief Executive Officer Dr. Christian Itin
Jefferies Global Healthcare Conference
Date and time: June 3, 2026; 10:30am EDT / 3:30pm BST
Location: New York, NY
Presenter: Chief Executive Officer Dr. Christian Itin
Webcasts of the presentations will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcasts will be archived on the Company’s website for 90 days following the presentations.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
